TerminatedNot Applicable

Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome

Stopped: Low Enrollment

United States20 participantsStarted 2019-09-30

Plain-language summary

The purpose of this study is to determine if peripheral nerve ultrasound can be used as a supplemental tool to diagnose Guillain-Barre syndrome (GBS) in the acute setting and aid in prognostication.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * For GBS group: Inpatients with acute, progressive weakness and no alternative diagnosis, with onset less than 30 days prior to examination. * For control group: Hospitalized patients on the inpatient neurology service who are being treated for non-peripheral nerve disorders (e.g. epilepsy, multiple sclerosis, or stroke). * For all subjects: 18+ years of age Exclusion Criteria: \- Patients with any history of multifocal motor neuropathy (MMN), prior Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), or hereditary neuropathy (e.g. Charcot-Marie-Tooth)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Internerve Variability of Cross-sectional Area (CSA) in Patients With GBS vs Controls

Timeframe: Day 0 and approximately 7 days after admission

Median Nerve Intranerve Cross-sectional Area (CSA) Variability in Patients With GBS vs Controls

Timeframe: Day 0 and approximately 7 days after admission

Ulnar Nerve Intranerve Cross-sectional Area (CSA) Variability in Patients With GBS vs Controls

Timeframe: Day 0 and approximately 7 days after admission

Trial details

NCT IDNCT04053452

SponsorDuke University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-07-04

Results submitted2025-03-18

View on ClinicalTrials.gov More Guillain-Barre Syndrome trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Internerve Variability of Cross-sectional Area (CSA) in Patients With GBS vs Controls

Timeframe: Day 0 and approximately 7 days after admission

Median Nerve Intranerve Cross-sectional Area (CSA) Variability in Patients With GBS vs Controls

Timeframe: Day 0 and approximately 7 days after admission

Ulnar Nerve Intranerve Cross-sectional Area (CSA) Variability in Patients With GBS vs Controls

Timeframe: Day 0 and approximately 7 days after admission